Dermatology, Data and Informatics AND High-Risk Skin Cancer

Vol. 38. No. 1


Roberto A Novoa, MD | Siegrid S Yu


The ability to capture, store, and analyze vast amounts of data has revolutionized human endeavors, and medicine is no exception. Information technology has touched every aspect of medicine, and this influence will only grow over time. However, a clinical dermatologist in practice today only sees the surface of this influence, through interactions with electronic medical records or through patients bringing the results of Internet searches to their visits. He or she will often miss the vast underlying structures that gird our system, that spur its advances, and that will continue to change the way we care for our patients. In this issue, we hope to shed light on these underlying methods, detailing the various roles of information technology in dermatology and what may lie ahead.


The majority of nonmelanoma skin cancers have excellent prognosis and are effectively treated with local, minimally invasive surgical or destructive techniques. However, the rising incidence of skin cancer combined with lengthened survival of the elderly, immunosuppressed, and at-risk populations has resulted in an increasing number of locally advanced, regional, and distantly metastatic disease. This subset of high-risk cases results in significant morbidity and mortality. As experts in skin cancers, dermatologists are at the forefront of the diagnosis, management, and investigation of novel therapies. Accurate diagnosis, risk stratification, staging, and a multidisciplinary approach are critical for optimizing patient outcome. Thank you to our colleagues in medical, surgical, and radiation oncology for the collaborative care of our most challenging patients.
In recent years, the development of targeted molecular therapy and immunotherapy has revolutionized the treatment of locally advanced and metastatic disease. I would like to thank the contributing authors for summarizing the advances in the field and providing us with knowledge regarding the management of high-risk skin cancer patients.


Department of Dermatology, Stanford University,
Stanford, California.
[email protected]

Professor of Dermatology
Director, Micrographic Surgery
and Dermatologic Oncology Fellowship
University of California, San Francisco

Seminars in Cutaneous Medicine and Surgery
publishes peer-reviewed information on the diagnosis and management of specific disorders of the skin, as well as the application of the latest scientific findings to patient care.
Most Read

Neuropathic Itch Jun 2011 | Vol. 30 | No. 2

Chronic itch can be caused by dysfunctions of itch-sensing neurons that produce sensory
hallucinations of pruritogenic stimuli. The cellular and molecular mechanisms are still
unknown. All neurological disease categories have been implicated, and neurological
causes should be considered for patients with otherwise-unexplained itch. The same
neurological illnesses that cause neuropathic pain can also or instead cause itch. These
include shingles (particularly of the head or neck), small-fiber polyneuropathies, radiculopathies
(eg, notalgia paresthetica and brachioradial pruritis), and diverse lesions of the
trigeminal nerve, root, and central tracts. Central nervous system lesions affecting sensory
pathways, including strokes, multiple sclerosis, and cavernous hemangiomas, can cause
central itch. Neuropathic itch is a potent trigger of reflex and volitional scratching although
this provides only fleeting relief. Rare patients whose lesion causes sensory loss as well as
neuropathic itch can scratch deeply enough to cause painless self-injury. The most common
location is on the face (trigeminal trophic syndrome). Treating neuropathic itch is
difficult; antihistamines, corticosteroids, and most pain medications are largely ineffective.
Current treatment recommendations include local or systemic administration of inhibitors
of neuronal excitability (especially local anesthetics) and barriers to reduce scratching.
Semin Cutan Med Surg 30:87-92 © 2011 Elsevier Inc. All rights reserved.

Differential diagnosis and management of oral ulcers Dec 2015 | Vol. 34 | No. 4

The diagnosis and treatment of oral lesions is often challenging due to the clinician’s limited exposure to the conditions that may cause the lesions and their similar appearances. While many oral ulcers are the result of chronic trauma, some may indicate an underlying systemic condition such as a gastrointestinal dysfunction, malignancy, immunologic abnormality, or cutaneous disease. Correctly establishing a definitive diagnosis is of major importance to clinicians who manage patients with oral mucosal disease. Some of these diseases are infectious; however, most are chronic, symptomatic, and desquamative. Treatment and management requires an understanding of the immunopathologic nature of the lesion. This review will address how to differentiate and diagnose varying types of oral ulcers and provide a treatment strategy. 
Semin Cutan Med Surg 34:171-177 © 2015 Frontline Medical Communications

Low-Level Laser (Light) Therapy (LLLT) in Skin: Stimulating, Healing, Restoring Mar 2013 | Vol. 32 | No. 1

Low-level laser (light) therapy (LLLT) is a fast-growing technology used to treat a multitude
of conditions that require stimulation of healing, relief of pain and inflammation, and
restoration of function. Although skin is naturally exposed to light more than any other
organ, it still responds well to red and near-infrared wavelengths. The photons are absorbed
by mitochondrial chromophores in skin cells. Consequently, electron transport, adenosine
triphosphate nitric oxide release, blood flow, reactive oxygen species increase, and diverse
signaling pathways are activated. Stem cells can be activated, allowing increased tissue
repair and healing. In dermatology, LLLT has beneficial effects on wrinkles, acne scars,
hypertrophic scars, and healing of burns. LLLT can reduce UV damage both as a treatment
and as a prophylactic measure. In pigmentary disorders such as vitiligo, LLLT can increase
pigmentation by stimulating melanocyte proliferation and reduce depigmentation by inhibiting
autoimmunity. Inflammatory diseases such as psoriasis and acne can also be managed.
The noninvasive nature and almost complete absence of side effects encourage
further testing in dermatology.
Semin Cutan Med Surg 32:41-52 © 2013 Frontline Medical Communications

Alopecia areata update Jun 2015 | Vol. 34 | No. 2

There is neither a cure for alopecia areata (AA) nor any universally proven therapy that induces and sustains remission in patients afflicted with this autoimmune disease. AA is characterized as a nonscarring alopecia which affects children and adults. It can be relatively easy to treat when the disease is patchy and limited; but when children and adults present with long standing extensive scalp and body hair loss, successful management can be challenging. Of the treatment choices available, physicians and midlevel providers usually select a cost-effective treatment approach based on disease duration, disease activity, age of the patient, and disease extent. In this manuscript, the clinical presentation, epidemiology, pathophysiology, plus current and evolving treatments for AA will be reviewed. Semin Cutan Med Surg 34:72-75 © 2015 Frontline Medical Communications

Treating Acne in Adult Women Jun 2018 | Vol. 37 | No. 3

Although acne most often appears in adolescence, it can continue into adulthood or can develop de novo during that stage of life.

Statement of Purpose

Seminars in Cutaneous Medicine and Surgery presents well-rounded and authoritative discussions of important clinical areas, especially those undergoing rapid change in the specialty. Each issue, under the direction of the Editors and Guest Editors selected because of their expertise in the subject area, includes the most current information on the diagnosis and management of specific disorders of the skin, as well as the application of the latest scientific findings to patient care.